|
시장보고서
상품코드
2075891
순환 종양 무세포 DNA 시장 : 종양 유형별, 암 유형별, 기술별, 용도별, 지역별Circulating Cell-Free Tumor DNA Market, by Tumor Type, by Cancer Type by Technology, by Application, and by Region |
||||||
순환 종양 무세포 DNA 시장은 2026년에 113억 5,000만 달러 규모에 이를 것으로 추정되며, 2033년까지 486억 2,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 23.1%로 성장할 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 113억 5,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 23.10% | 예측 금액(2033년) | 486억 2,000만 달러 |
순환 종양 DNA(ctDNA)란, 혈류를 통해 순환하는 악성 세포나 종양에서 유래한 DNA를 말합니다. 세포의 핵에는 DNA의 대부분이 포함되어 있습니다. 종양이 커짐에 따라 세포는 사멸하고 새로운 세포로 대체됩니다. 분해된 사멸 세포는 DNA를 포함한 그 내용물을 혈류로 방출합니다. ctDNA는 일반적으로 길이가 200 뉴클레오티드 미만인 DNA의 짧은 단임베디드니다. ctDNA의 양은 사람마다 다르며, 종양의 유형, 위치, 그리고 악성 종양의 경우 병기에도 영향을 받습니다. 순환 종양 DNA(ctDNA)에는 일반적으로 암을 발견하는 데 도움이 될 수 있는 유전적 변이가 포함되어 있습니다. ctDNA의 그 밖의 중요한 용도로는 예후 예측, 치료 효과 모니터링, 종양 부피 추정 등이 있습니다. 새로운 암 검출 검사가, 완치율이 가장 높은 무증상 초기 단계에서 암을 발견할 수 있다면, 그 임상적 유용성은 최대가 됩니다. 순환 종양 DNA 분석은 암의 조기 발견에 도움이 되며, 분자 표적 치료의 제공에도 활용되고 있습니다.
시장 역학
시장의 주요 기업들이 제품 포트폴리오를 확대하기 위해 신제품을 출시하는 등 유기적 성장 전략을 채택하는 추세가 확산되고 있는 것이, 예측 기간 동안 시장 성장을 견인할 것으로 예측됩니다. 예를 들어, 2022년 7월, 차세대 분자진단 기업인 BillionToOne Inc.는 자사 최초의 암 액체 생검 제품인 Northstar Select와 Northstar Response의 출시를 발표했습니다. 이 제품들은 현재 특정 학술 암 센터에서 연구 목적으로 사용할 수 있습니다. Northstar Select는 종합적인 범암종 체세포 돌연변이 프로파일링 패널입니다. BillionToOne이 독자적으로 개발한 분자 계수 기술, 즉 Quantitative Counting Templates(QCTs)를 활용함으로써, 이 패널은 치료에 활용 가능한 변이 식별에 있어 탁월한 검출 한계를 실현하고 있습니다. 한편, Northstar Response는 메틸화를 기반으로 하는 조직에 구애받지 않는 치료 반응 모니터링 분석법입니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 세계 순환 종양 무세포 DNA 시장의 주요 기업 프로파일을 분석했습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 시장 보고서는 투자자, 공급업체, 제품 제조업체, 판매업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 순환 종양 무세포 DNA 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 수월하게 내릴 수 있습니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 순환 종양 무세포 DNA 시장 : 종양 유형별(2021-2033년)
제5장 세계의 순환 종양 무세포 DNA 시장 : 암 유형별(2021-2033년)
제6장 세계의 순환 종양 무세포 DNA 시장 : 기술별(2021-2033년)
제7장 세계의 순환 종양 무세포 DNA 시장 : 용도별(2021-2033년)
제8장 세계의 순환 종양 무세포 DNA 시장 : 지역별(2021-2033년)
제9장 경쟁 구도
제10장 섹션
AJY 26.07.09Circulating Cell-Free Tumor DNA Market is estimated to be valued at USD 11.35 Bn in 2026 and is expected to reach USD 48.62 Bn by 2033, growing at a compound annual growth rate (CAGR) of 23.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 11.35 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 23.10% | 2033 Value Projection: | USD 48.62 Bn |
The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.
Market Dynamics
Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market
Detailed Segmentation:
- Global Circulating Cell-Free Tumor DNA Market, By Tumor Type (Revenue, USD Bn, 2021 - 2033)
- Malignant Tumors
- Precancerous Tumors
- Global Circulating Cell-Free Tumor DNA Market, By Cancer Type (Revenue, USD Bn, 2021 - 2033)
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
- Global Circulating Cell-Free Tumor DNA Market, By Technology (Revenue, USD Bn, 2021 - 2033)
- PCR
- Massively Parallel Sequencing
- Single Nucleotide Polymorphism
- Global Circulating Cell-Free Tumor DNA Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Cancer Diagnosis
- Targeting Therapeutics
- Prognosis Indication
- Global Circulating Cell-Free Tumor DNA Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Biocept, Inc.
- Illumina, Inc.
- Quest Diagnostics Incorporated
- KURABO INDUSTRIES LTD
- PerkinElmer chemagen Technologie GmbH
- Biodesix
- Guardant Health
- QIAGEN
- Sequenom, Inc.
- Agilent Technologies, Inc.
- Fluxion Biosciences Inc.
- Natera, Inc.
- Agena Bioscience, Inc.
- Paragon Genomics, Inc.
- Lucence Health Inc.
- Eurofins Genomics
- Thermo Fisher Scientific
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Tumor Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product Launch
- Technological Advancements
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
4. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Malignant Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Precancerous Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
5. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segments Trends
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
6. Global Circulating Cell-free Tumor DNA Market, By Technology, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segments Trends
- PCR
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Massively Parallel Sequencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Single Nucleotide Polymorphism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
7. Global Circulating Cell-free Tumor DNA Market, By Application, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cancer Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Targeting Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Prognosis Indication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
8. Global Circulating Cell-free Tumor DNA Market, By Region, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Billion)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Biocept, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Quest Diagnostics Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- KURABO INDUSTRIES LTD
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PerkinElmer chemagen Technologie GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biodesix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Guardant Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- QIAGEN
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sequenom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Agilent Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Fluxion Biosciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Natera, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Agena Bioscience, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Paragon Genomics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lucence Health Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eurofins Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
